The validity of progression‐free survival 2 as a surrogate trial end point for overall survival
Abstract
Background: Overall survival (OS) is the gold‐standard end point for oncology trials. However, the availability of multiple therapeutic options after progression and crossover to receive investigational agents confound and delay OS data maturation. Progression‐free survival 2 (PFS‐2), defined as the time from randomization to progression on first subsequent therapy, has been proposed as a surrogate for OS. Using a meta‐analytic approach, the authors aimed to assess the association between OS and PFS‐2 and compare this with progression‐free survival 1 (PFS‐1) and the objective response rate (ORR).Methods: An electronic literature search was performed to identify randomized trials of systemic therapies in advanced solid tumors that reported PFS‐2 as a prespecified end point. Correlations between OS and PFS‐2, OS and PFS‐1, and OS and ORR as hazard ratios (HRs) or odds ratios (ORs) were assessed via linear regression weighted by trial size.Results: Thirty‐eight trials were included, and they comprised 19,031 patients across 8 tumor types. PFS‐2 displayed a moderate correlation with OS (r = 0.67; 95% confidence interval [CI], 0.08‐0.69). Conversely, correlations of ORR (r = 0.12; 95% CI, 0.00‐0.13) and PFS‐1 (r = 0.21; 95% CI, 0.00‐0.33) were poor. The findings for PFS‐2 were consistent for subgroup analyses by treatment type (immunotherapy vs nonimmunotherapy: r = 0.67 vs 0.67), survival post progression (r = 0.86 vs 0.79), and percentage not receiving subsequent treatment (r = 0.70 vs 0.63).Conclusions: Across diverse tumors and therapies, the treatment effect on PFS‐2 correlated moderately with the treatment effect on OS. PFS‐2 performed consistently better than PFS‐1 and ORR, regardless of postprogression treatment and postprogression survival. PFS‐2 should be included as a key trial end point in future randomized trials of solid tumors.Keywords
This publication has 24 references indexed in Scilit:
- Mechanisms and insights into drug resistance in cancerFrontiers in Pharmacology, 2013
- Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation StudyTherapeutic Innovation & Regulatory Science, 2013
- Progression-Free Survival: Meaningful or Simply Measurable?Journal of Clinical Oncology, 2012
- Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Annals of Oncology, 2010
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free SurvivalJNCI: Journal of the National Cancer Institute, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancerBritish Journal of Cancer, 2008
- Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Analysis of progression‐free survival in oncology trials: some common statistical issuesPharmaceutical Statistics, 2007
- Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validationPharmaceutical Statistics, 2006